<DOC>
	<DOC>NCT01125683</DOC>
	<brief_summary>The purpose of this study is to evaluate whether treatment with single and multiple oral doses of AZD1446 for 1 week will have effect on Quantified Electroencephalography and Event-Related Potentials in patients with Alzheimers Disease. The total treatment period is 9 weeks, divided into 5 equally long sub-periods of 7 days and 4 wash-out periods of 7 days each.</brief_summary>
	<brief_title>To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Clinical diagnosis of probable Alzheimer´s Disease Hachinski Ischaemic score &lt; 4 MSE score 18 to 24 History of any clinically significant disease or dementia other than Alzheimer´s Disease Current major depressive disorder or other major psychiatric disorders</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Alzheimer's disease</keyword>
	<keyword>EEG</keyword>
	<keyword>cognition</keyword>
	<keyword>pharmacodynamic</keyword>
</DOC>